Get the Stockscreener App
1.72
0.58%
-0.01
Citius Oncology Inc stock is traded at $1.72, with a volume of 57,627.
It is down -0.58% in the last 24 hours and down -15.27% over the past month.
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.
See More
Previous Close:
$1.73
Open:
$1.76
24h Volume:
57,627
Relative Volume:
0.24
Market Cap:
$134.80M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+0.00%
1M Performance:
-15.27%
6M Performance:
+98.11%
1Y Performance:
+45.15%
1-Day Range:
$1.715
$1.78
1-Week Range:
$1.68
$1.93
52-Week Range:
$0.5506
$6.19
Citius Oncology Inc Stock (CTOR) Company Profile
Name
Citius Oncology Inc
Sector
Phone
(908) 967-6677
Address
11 COMMERCE DRIVE, CRANFORD
Compare CTOR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTOR
Citius Oncology Inc
|
1.72 | 144.48M | 0 | 0 | 0 | 0.00 |
|
ZTS
Zoetis Inc
|
143.89 | 63.86B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.38 | 41.80B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.245 | 40.88B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.11 | 22.98B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
442.37 | 19.53B | 3.08B | 1.24B | 1.07B | 25.61 |
Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-23-25 | Upgrade | Maxim Group | Hold → Buy |
| Nov-27-24 | Initiated | Maxim Group | Buy |
Citius Oncology Inc Stock (CTOR) Latest News
Building trade automation scripts for Citius Oncology Inc.Weekly Trading Summary & Stock Portfolio Risk Management - newser.com
Regression analysis insights on Citius Oncology Inc. performanceMarket Volume Report & Detailed Earnings Play Strategies - newser.com
Predicting Citius Oncology Inc. trend using moving averagesMarket Sentiment Summary & Daily Profit Focused Stock Screening - newser.com
Why retail investors favor Citius Oncology Inc. stockQuarterly Earnings Report & Technical Pattern Recognition Alerts - newser.com
Real time social sentiment graph for Citius Oncology Inc.2025 Market Sentiment & Community Consensus Trade Alerts - newser.com
What the charts say about Citius Oncology Inc. todayTrade Volume Report & Weekly Market Pulse Updates - newser.com
What data driven models say about Citius Oncology Inc.’s futureAnalyst Downgrade & Weekly Watchlist for Hot Stocks - newser.com
News impact scoring models applied to Citius Oncology Inc.2025 Short Interest & Reliable Price Action Trade Plans - newser.com
How Citius Oncology Inc. stock benefits from strong dollarJuly 2025 Momentum & Entry and Exit Point Strategies - newser.com
Published on: 2025-10-29 00:05:52 - newser.com
Published on: 2025-10-28 05:08:21 - newser.com
Is Citius Oncology Inc. stock a buy on dipsM&A Rumor & Weekly High Momentum Picks - Fundação Cultural do Pará
What high frequency data says about Citius Oncology Inc.Trend Reversal & Entry and Exit Point Strategies - newser.com
Is Citius Oncology Inc. stock attractive for long term wealth buildingAnalyst Upgrade & Community Verified Watchlist Alerts - newser.com
Citius Oncology Stockholders Approve Share Increase - TipRanks
Citius Oncology Inc Stock (CTOR) Financials Data
There is no financial data for Citius Oncology Inc (CTOR). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
2.97%
0.99%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):